Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score.
about
Clinical outcome measures in juvenile idiopathic arthritisFinding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre studyAdvances in the treatment of polyarticular juvenile idiopathic arthritisPredictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of ChildrFluorescence optical imaging and musculoskeletal ultrasonography in juvenile idiopathic polyarticular disease before and during antirheumatic treatment - a multicenter non-interventional diagnostic evaluation.Temporomandibular joint involvement in Juvenile Idiopathic Arthritis: reliability and validity of a screening protocol for the rheumatologistJuvenile spondyloarthritis.Evaluation and Treatment of Childhood Enthesitis-Related Arthritis.Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study.Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administrationTrends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children and young people with Juvenile Idiopathic Arthritis: results from the childhood arthritis prospective Study.Assessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists.Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanerceptRecent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis.Use of databases for clinical research.Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases.How common is remission in juvenile idiopathic arthritis: A systematic review.How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition.Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.Juvenile arthritis disease activity score is a better reflector of active disease than the disease activity score 28 in adults with polyarticular juvenile idiopathic arthritis.Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score.Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score.Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis.Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.It is worth including assessment of disease activity state in juvenile arthritis clinical trials.Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study.Physical activity, functional ability, and disease activity in children and adolescents with juvenile idiopathic arthritis.Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.Inflammatory Markers and Disease Activity in Juvenile Idiopathic Arthritis.Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure.Using the Juvenile Arthritis Disease Activity Score based on erythrocyte sedimentation rate or C-reactive protein level: results from the Portuguese register.Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.[Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].Vitamin D and juvenile idiopathic arthritis.The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON).A Granulocyte-Specific Protein S100A12 as a Potential Prognostic Factor Affecting Aggressiveness of Therapy in Patients with Juvenile Idiopathic Arthritis
P2860
Q26752701-F1DE047B-C7A2-4370-B2AC-618A406E0BD9Q26786198-C871076F-7236-4A36-AB56-F34E09ACA972Q27001017-48E9DC71-A6D8-4296-A282-B73ADAFC0178Q33801499-4CAB6675-F8B3-4C67-B986-80E42D9D269CQ33859243-0F5B4325-89E6-484A-A5BF-D5A5B3B0A4D4Q35623758-C9F1B7D0-BCF5-45A3-9CA2-40ECE9FB4054Q35800954-1B71AA8E-A544-40D5-ACC2-E8642C79B0FCQ36498631-54029D7D-135B-4B56-B7F9-1D82744CC606Q36552356-F8FA76F9-2DE6-4CA2-8302-85CA70BA1909Q37006464-CC085503-607C-45D1-ACD0-DC22122C572DQ37014830-53C19C03-2D55-4BA2-877E-090456B42AB2Q37428914-29A710E5-7741-4037-B01A-B399C3528320Q37436386-A809EA49-34DD-473A-9C96-8909EFBB1C00Q37518319-C24C3848-9EAF-4DF3-8272-C57BC7722445Q38102977-4A0EAAFD-3DBC-4915-843D-99CCE0760A78Q38184532-6B12E77F-78A3-48A8-966D-A3A092DEF918Q38697343-A4687D2B-4848-48E7-B23B-B955661CB8F9Q38720413-A09CD4EE-B3A6-4AE5-815C-283440977369Q38847169-B8DA8F90-6651-4C6E-890A-BED2EA71E9FCQ41311218-99C5B050-F6F7-4A5C-99B3-8EA9F931A914Q42957810-D65E1DBB-EDA5-486E-AE0B-089F8304E206Q43484603-5B12334B-2BAC-4207-B43E-781E7F93BBCDQ44513624-16C65552-64C2-4831-8DED-95B097BE3233Q44953141-5B72AE71-F6E8-475D-8D77-82CD9F842C1CQ46231376-D63DF4B2-FEA1-4D07-A28C-C13506197B77Q46709771-6C871366-E222-4C34-A2B4-32EB183E17BAQ47111826-A7F546F9-7474-4861-912F-9783A95B88B1Q47582373-EEAC436A-12A0-49C3-9516-5DDE80E52513Q48082446-92C1E7E0-0449-445D-B4C0-2D5CE3A8265EQ48514200-46A3AC2F-6F80-4CFC-B271-1F7249D6B052Q50905430-6FA9EEA6-A0AB-4CD3-884D-4076A1E2AED4Q51055393-44DABDDA-0CE7-4973-9DEB-418BB0E7671BQ51104549-B5152BBA-A72C-479D-B804-93BEADBF1539Q51425096-C0280A82-748D-4F04-A102-83C15C1896B1Q52685007-F74386D4-F8E9-46C0-AD81-4347569C6A1DQ52874762-CED88517-FA61-459B-A1B0-39E2B123A5F5Q55003369-41A9F268-D1A3-448E-8613-F9486A4DE46DQ55192377-49CF742A-1574-464F-A283-D71BFB5550FEQ58694039-1C365E67-A8C2-4DD4-970B-A59186E3ADEE
P2860
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Remission, minimal disease act ...... hritis disease activity score.
@en
Remission, minimal disease act ...... hritis disease activity score.
@nl
type
label
Remission, minimal disease act ...... hritis disease activity score.
@en
Remission, minimal disease act ...... hritis disease activity score.
@nl
prefLabel
Remission, minimal disease act ...... hritis disease activity score.
@en
Remission, minimal disease act ...... hritis disease activity score.
@nl
P2093
P2860
P356
P1476
Remission, minimal disease act ...... hritis disease activity score.
@en
P2093
Alberto Martini
Alessandro Consolaro
Angela Pistorio
Angelo Ravelli
Clara Malattia
Giulia Bracciolini
Paediatric Rheumatology International Trials Organization
Sergio Davì
Silvia Magni-Manzoni
Silvia Pederzoli
P2860
P304
P356
10.1002/ART.34373
P577
2012-07-01T00:00:00Z